Nevro (NVRO) to Release Earnings on Tuesday

Nevro (NYSE:NVRO - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Nevro to post earnings of ($1.02) per share for the quarter. Nevro has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Persons interested in registering for the company's earnings conference call can do so using this link.

Nevro (NYSE:NVRO - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.35. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. The firm had revenue of $116.18 million during the quarter, compared to the consensus estimate of $115.93 million. On average, analysts expect Nevro to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nevro Stock Down 7.4 %

NVRO traded down $0.84 during midday trading on Tuesday, hitting $10.58. The company had a trading volume of 757,084 shares, compared to its average volume of 474,593. Nevro has a 52 week low of $10.54 and a 52 week high of $29.77. The company has a quick ratio of 4.94, a current ratio of 6.37 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $388.07 million, a price-to-earnings ratio of -4.12 and a beta of 0.89. The stock's 50 day moving average price is $13.82 and its 200 day moving average price is $16.51.

Analyst Ratings Changes

NVRO has been the subject of several recent research reports. Mizuho decreased their target price on shares of Nevro from $20.00 to $16.00 and set a "neutral" rating for the company in a research report on Thursday, April 11th. Robert W. Baird reduced their price objective on shares of Nevro from $23.00 to $19.00 and set a "neutral" rating for the company in a research report on Thursday, February 22nd. Wells Fargo & Company reduced their price objective on shares of Nevro from $17.00 to $14.00 and set an "equal weight" rating for the company in a research report on Monday, April 8th. Citigroup reduced their price objective on shares of Nevro from $18.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, April 3rd. Finally, Royal Bank of Canada reduced their price objective on shares of Nevro from $18.00 to $16.00 and set a "sector perform" rating for the company in a research report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Nevro currently has an average rating of "Hold" and a consensus target price of $21.23.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.